Jundishapur Journal of Microbiology

Published by: Kowsar

Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

Zohreh Aminzadeh 1 , 2 , Davood Yadegarynia 1 , Alireza Fatemi 1 , * , Elham Tahmasebian Dehkordi 1 and Saeed Azad Armaki 1
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia
Article information
  • Jundishapur Journal of Microbiology: October 01, 2014, 7 (10); e12831
  • Published Online: October 1, 2014
  • Article Type: Brief Report
  • Received: June 11, 2013
  • Revised: July 8, 2013
  • Accepted: July 11, 2013
  • DOI: 10.5812/jjm.12831

To Cite: Aminzadeh Z, Yadegarynia D, Fatemi A, Tahmasebian Dehkordi E, Azad Armaki S. Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?, Jundishapur J Microbiol. 2014 ; 7(10):e12831. doi: 10.5812/jjm.12831.

Abstract
Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166(19): 2138-44[DOI][PubMed]
  • 2. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32(8): 470-85[DOI][PubMed]
  • 3. Shukla SK. Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin Med Res. 2005; 3(2): 57-60[PubMed]
  • 4. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006; 42 Suppl 1-7[DOI][PubMed]
  • 5. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092): 1670-3[DOI][PubMed]
  • 6. Clinical and Laboratory Standards Institute (CLSI) . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard . 2006;
  • 7. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46(2): 193-200[DOI][PubMed]
  • 8. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RJ, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42(6): 2398-402[DOI][PubMed]
  • 9. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008; 52(9): 3315-20[DOI][PubMed]
  • 10. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38(3): 448-51[DOI][PubMed]
  • 11. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009; 199(5): 619-24[DOI][PubMed]
  • 12. Clinical and Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard. 2012;
  • 13. Pastagia M, Kleinman LC, Lacerda de la Cruz EG, Jenkins SG. Predicting risk for death from MRSA bacteremia. Emerg Infect Dis. 2012; 18(7): 1072-80[DOI][PubMed]
  • 14. Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mug/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011; 17(1): 52-7[DOI][PubMed]
  • 15. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One. 2011; 6(6)[DOI][PubMed]
  • 16. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54(6): 755-71[DOI][PubMed]
  • 17. Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol. 2008; 46(9): 3042-7[DOI][PubMed]
  • 18. Sharpe JN, Shively EH, Polk HC, Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005; 189(4): 425-8[DOI][PubMed]
  • 19. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49(6): 2260-6[DOI][PubMed]
  • 20. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005; 40(11): 1601-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments